The single payer form of health insurance for all Americans: could this be the year that the long-debated model for medical care coverage becomes a reality? Dr. David Himmelstein, associate professor of medicine at Harvard Medical School and a long-time advocate of single payer coverage, tells the Chicago Tribune's Bruce Japsen about the best chance in years for this model in the healthcare reform debate.
Single Payer Health Coverage's Fighting Chance
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
The single payer form of health insurance for all Americans: could this be the year that the long-debated model for medical care coverage becomes a reality? Dr. David Himmelstein, associate professor of medicine at Harvard Medical School and a long-time advocate of single payer coverage, tells the Chicago Tribune's Bruce Japsen about the best chance in years for this model in the healthcare reform debate.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE Broadcast Replay
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
1.00 credits
<p>Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
1.25 credits
<p>Clinical Conundrums in ARIA: Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?